FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 20:36:30 17/05/2024 BST | ||
| 0.023 EUR | -11.54% |
|
| Current month | -69.33% | ||
| 1 month | -70.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 0.023 | -11.54% |
| 16/05/24 | 0.026 | -3.70% |
| 15/05/24 | 0.027 | -20.59% |
| 14/05/24 | 0.034 | +3.03% |
| 13/05/24 | 0.033 | -13.16% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 08:36 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SQ4S6H |
| ISIN | DE000SQ4S6H0 |
| Date issued | 24/11/2022 |
| Strike | 321.3 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.33 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.99 € |
|---|---|
| Lowest since issue | 0.023 € |
| Spread | 0.01 € |
| Spread % | 30.30% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat
